Sepsis due to linezolid resistant Staphylococcus cohnii and Staphylococcus kloosii: First reports of linezolid resistance in coagulase negative staphylococci from India

Peer, MA; Nasir, RA; Kakru, DK; Fomda, BA; Bashir, Gulnaz; Sheikh, Ijaz

doi:10.4103/0255-0857.76527

Cited by 30 publications

(23 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3] The first case linezolid-resistant staphylococci appeared within 1 year after linezolid was approved for use for treatment. [5] Here we report two linezolidresistant coagulase negative staphylococcal strains which were isolated in June 2010 at our hospital. [5] Here we report two linezolidresistant coagulase negative staphylococcal strains which were isolated in June 2010 at our hospital.…”

Section: Linezolid-resistantmentioning

confidence: 89%

Linezolid-resistant Staphylococcus spp. at a tertiary care hospital of Andhra Pradesh

Kalawat

Sharma

Reddy

2011

Indian Journal of Medical Microbiology

View full text Add to dashboard Cite

Section: Linezolid-resistantmentioning

confidence: 89%

Linezolid-resistant Staphylococcus spp. at a tertiary care hospital of Andhra Pradesh

Kalawat

Sharma

Reddy

2011

Indian Journal of Medical Microbiology

View full text Add to dashboard Cite

“…(MRS) strains with intrinsic resistance to methicillin and all beta-lactam antibiotics are emerging pathogens in hospitalized diabetic patients. [27] Linezolid, a novel synthetic antibiotic, is considered one of the few effective ways to treat severe methicillin-resistant infections in critically ill patients. Recently, linezolid resistance is reported in our country which may be a consequence of prolonged and injudicious use of this drug[2728] and is an imperative threat to lose an effective and safe drug for treating MRS. HLAR in Enterococcus spp.…”

Section: Discussionmentioning

confidence: 99%

Bacteriological and resistance profile in isolates from diabetic patients

et al. 2012

View full text Add to dashboard Cite

Background:Diabetes mellitus has become a global epidemic illness and poses a threat for development of resistant bacterial infections.Aim:This study was aimed to know the bacteriological and resistance profile of isolates obtained from diabetic patients.Materials and Methods:The bacterial isolates obtained from various samples of diabetic patients admitted in medicine department in 6-month period were identified and tested for antibiotic susceptibility. The extended spectrum beta-lactamases (ESβL), AmpC, and metallo-beta-lactamases (MβL) enzymes were detected in gram-negative bacilli. Methicillin, macrolide-lincosamide-streptogramin (MLS), and linezolid resistance in Staphylococcus spp. were detected. High-level aminoglycoside resistance (HLAR) in Enterococcus spp. was also tested.Results:In all, 38 of 125 diabetic patients (30.4%) had bacterial infection, 18 patients had wound infections, 18 had urinary tract infections (UTIs), and 2 had respiratory tract infections. Escherichia coli among gram-negative bacteria and Staphylococcus aureus among gram-positive bacteria were the predominant pathogens. 32.5% gram-negative bacilli were AmpC producers, 37.5% were MβL producers, and 40% were ESβL producers. Methicillin and MLS resistance was found in 50% and 33.3% isolates of Staphylococcus spp., respectively. HLAR resistance was alarming in Enterococcus spp. Polymyxin among gram-negative bacteria and vancomycin for gram-positive bacteria were the last resort with highest susceptibility rates to treat infections among diabetic patients.Conclusion:Resistant bacterial infections in diabetic patients are common. The presence of various resistance mechanisms in isolates of our study shows that therapeutic failure can occur if empirical prescription is unsubstantiated.

show abstract

“…Although linezolid resistance in S. aureus is uncommon, emergence has been shown from some parts of the world [33]. From India, first case report of linezolid resistance was published in 2011 from Kashmir [34]. Present research has found 0.9% (3) VRSA in the MRSA, comparatively higher than that shown from north part of India [35].…”

Section: S Aureus Is a Leading Pathogen In Hospital Acquired Infectimentioning

confidence: 73%

Prevalence and Drug Resistance Pattern of Staphylococcus aureus Clinical Isolates in Bastar Region

Khan¹

2015

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetAmaç: Bu araştırmanın amacı Bastar bölgedeki yaygınlığını ve S. aureus antibiyotik direncini etüd edilerek. Gereç ve Yöntem: Ocak 2010-Mayıs 2012 tarihinden itibaren, 916 S. aureus izolatı kültüre klinik örneklerden standart testlerle tespit edilmiştir. MRSA tespit oksasilin ekran ağar tarafından yapı-lan ve sefoksitin disk difüzyon testleri yapıldı. Kirby-Bauer disk difüzyon testi antibiyotik duyarlılık incelemek için kullanılmıştır. Vankomisin MIC ve linezolid Etest tarafından incelendi. Bulgular: Izolatların % 34.8 MRSA idi. MRSA izolatları içinde,% 63 (165) eritromisine dirençli bulunmuştur, azitromisine % 39.3 (103), klindamisin için % 61.8 (162), % 81.5 (260) kotrimoksazol için, % 0.6 (2) linezolide, % 0.9 (3) vankomisine, % 76.5 (244) tetrasiklin, % 67.7 (216) gentamisin için % 63.3 (202) siprofloksasin, % 8.5 (27) gatifloksasin için, % 16.4 (43), kloramfenikol % 68.4 (39 ) norfloksasin nitrofurantoine % 12.3 (7), Sulfısoxazol için % 80.7 (46) ve % 80.7 (46) antibiyotik trimetoprim için. Tartışma: Çalışması bu bölgeden ilk kez yapıldı. Prevalans ve ilaç direnci oranı diğer çalışmalar ile karşılaştırılmıştır. Linezolid direncinin ortaya çık-ması ve MRSA izolatlarının görece yüksek vankomisin direnci bu çalışmanın endişe verici bir bulgudur. Kotrimoksazol ve/veya gentamisin ilk ampirik tedavisi olarak kabul edilebilir, ancak Antibiyograma göre doğru bir antibiyotik ile hemen değiştirilmelidir. Anahtar KelimelerBastar; MRSA; Prevalans; İlaç Direnci Abstract Aim: The aim of this research was to study the prevalence and antibiotic resistance of S. aureus in the Bastar region. Material and Method: From the clinical samples cultured from Jan 2010 to May 2012, 916 S. aureus isolates were identified by the standard tests. Screening of MRSA was done by oxacillin screen agar and cefoxitin disk diffusion tests. Antibiotic susceptibility was examined by Kirby-Bauer disk diffusion test. For MIC of vancomycin and linezolid, Etest was performed. Result: Of the isolates, 34.8% were MRSA. In the MRSA isolates, 63% (165) were found resistant to erythromycin, 39.3% (103) to azithromycin, 61.8% (162) to clindamycin, 81.5% (260) to cotrimoxazole, 0.6% (2) to linezolid, 0.9% (3) to vancomycin, 76.5% (244) to tetracycline, 67.7% (216) to gentamycin, 63.3% (202) to ciprofloxacin, 8.5% (27) to gatifloxacin, 16.4% (43) to chloramphenicol, 68.4% (39) to norfloxacin, 12.3% (7) to nitrofurantoin, 80.7% (46) to sulfisoxazole, and 80.7% (46) to trimethoprim antibiotics. Discussion: The study was conducted first time from this region. The prevalence and drug resistance percentage is compared with other studies. Emergence of linezolid resistance and relatively higher vancomycin resistance in the MRSA isolates is a worrisome finding of this study. Cotrimoxazole and/or gentamycin may be considered as initial empiric treatment, but must be replaced immediately with the correct antibiotic according to the antibiogram. Keywords IntroductionStaphylococcus aureus is a well known nosocomial pathogen and the methicillin resistance in the orga...

show abstract

Sepsis due to linezolid resistant Staphylococcus cohnii and Staphylococcus kloosii: First reports of linezolid resistance in coagulase negative staphylococci from India

Cited by 30 publications

References 12 publications

Linezolid-resistant Staphylococcus spp. at a tertiary care hospital of Andhra Pradesh

Linezolid-resistant Staphylococcus spp. at a tertiary care hospital of Andhra Pradesh

Bacteriological and resistance profile in isolates from diabetic patients

Prevalence and Drug Resistance Pattern of Staphylococcus aureus Clinical Isolates in Bastar Region

Contact Info

Product

Resources

About